EA202290154A1 - Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты - Google Patents

Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты

Info

Publication number
EA202290154A1
EA202290154A1 EA202290154A EA202290154A EA202290154A1 EA 202290154 A1 EA202290154 A1 EA 202290154A1 EA 202290154 A EA202290154 A EA 202290154A EA 202290154 A EA202290154 A EA 202290154A EA 202290154 A1 EA202290154 A1 EA 202290154A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pharmaceutical composition
myeloid leukemia
acute myeloid
chemotherapeutic agents
Prior art date
Application number
EA202290154A
Other languages
English (en)
Inventor
Ин Хван Бае
Дзи Йоунг Сонг
Дзае Юл Чой
Йоунг Гил Ахн
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of EA202290154A1 publication Critical patent/EA202290154A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В изобретении предлагаются фармацевтическая композиция для лечения миелоидного лейкоза (AML) и способ лечения острого миелоидного лейкоза с ее применением, при этом указанная фармацевтическая композиция содержит терапевтически эффективную комбинацию ингибитора Fms-подобной тирозинкиназы-3 (FLT3) или его фармацевтически приемлемой соли или сольвата, и химиотерапевтического агента или его фармацевтически приемлемой соли или сольвата.
EA202290154A 2019-06-27 2020-06-25 Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты EA202290154A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190077302 2019-06-27
PCT/KR2020/008258 WO2020262974A1 (ko) 2019-06-27 2020-06-25 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
EA202290154A1 true EA202290154A1 (ru) 2022-03-29

Family

ID=74060307

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202290154A EA202290154A1 (ru) 2019-06-27 2020-06-25 Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты

Country Status (11)

Country Link
US (1) US20220354842A1 (ru)
EP (1) EP3991733A4 (ru)
JP (1) JP2022538817A (ru)
KR (1) KR20210002015A (ru)
CN (1) CN114650823A (ru)
AU (1) AU2020308814A1 (ru)
CA (1) CA3145391A1 (ru)
EA (1) EA202290154A1 (ru)
IL (1) IL289366A (ru)
MX (1) MX2021015724A (ru)
WO (1) WO2020262974A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305178A (en) * 2021-02-26 2023-10-01 Tyra Biosciences Inc Aminopyrimidine compounds and methods of using them
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008111441A1 (ja) * 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
BRPI1013698A2 (pt) * 2009-03-23 2016-04-26 Ambit Biosciences Corp métodos para tratamento com o uso de terapia de combinação
EP2454257B1 (en) * 2009-07-15 2013-08-21 AbbVie Inc. Pyrrolopyridine inhibitors of kinases
JP2019512495A (ja) 2016-03-29 2019-05-16 アステラス製薬株式会社 急性骨髄性白血病の治療のための併用療法
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
PT3514153T (pt) 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Composto de pirimidina e utilização farmacêutica do mesmo
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
SG11202108867VA (en) * 2019-02-22 2021-09-29 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Also Published As

Publication number Publication date
EP3991733A4 (en) 2023-07-05
JP2022538817A (ja) 2022-09-06
WO2020262974A1 (ko) 2020-12-30
IL289366A (en) 2022-02-01
MX2021015724A (es) 2022-05-16
CN114650823A (zh) 2022-06-21
KR20210002015A (ko) 2021-01-06
US20220354842A1 (en) 2022-11-10
CA3145391A1 (en) 2020-12-30
EP3991733A1 (en) 2022-05-04
AU2020308814A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
EA202290154A1 (ru) Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
MX2023010411A (es) Inhibidores de erbb/btk.
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
EA200200208A1 (ru) Синергитическая композиция
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
MX2023008954A (es) Inhibidores de los receptores erbb.
EA202193015A1 (ru) Ингибиторы cdk
PH12021550713A1 (en) Medicament for the treatment of chronic cough
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021007247A (es) Derivados de rapamicina.
MX2022004027A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida.
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
EA202092146A1 (ru) Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора
PH12020551772A1 (en) Oxo-substituted compound
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2022008487A (es) Degradadores de smarca2-vhl.